HK1127282A1 - Solid dosage form of olmesartan medoxomil and amlodipine - Google Patents

Solid dosage form of olmesartan medoxomil and amlodipine

Info

Publication number
HK1127282A1
HK1127282A1 HK09104986.9A HK09104986A HK1127282A1 HK 1127282 A1 HK1127282 A1 HK 1127282A1 HK 09104986 A HK09104986 A HK 09104986A HK 1127282 A1 HK1127282 A1 HK 1127282A1
Authority
HK
Hong Kong
Prior art keywords
amlodipine
dosage form
solid dosage
olmesartan medoxomil
medoxomil
Prior art date
Application number
HK09104986.9A
Other languages
English (en)
Inventor
Wolfgang Bauer
Johann Lichey
Andreas Teubner
Elmar Wadenstorfer
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1127282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1127282A1 publication Critical patent/HK1127282A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK09104986.9A 2006-09-15 2009-06-03 Solid dosage form of olmesartan medoxomil and amlodipine HK1127282A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84509006P 2006-09-15 2006-09-15
PCT/GB2007/003933 WO2008032107A1 (en) 2006-09-15 2007-10-12 Solid dosage form of olmesartan medoxomil and amlodipine

Publications (1)

Publication Number Publication Date
HK1127282A1 true HK1127282A1 (en) 2009-09-25

Family

ID=38754721

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104986.9A HK1127282A1 (en) 2006-09-15 2009-06-03 Solid dosage form of olmesartan medoxomil and amlodipine

Country Status (23)

Country Link
US (2) US20090175942A1 (fi)
JP (1) JP5344620B2 (fi)
AT (1) AT509493B1 (fi)
AU (1) AU2007297333B2 (fi)
BR (1) BRPI0716893A2 (fi)
CH (1) CH703897B1 (fi)
DE (1) DE212007000063U1 (fi)
DK (1) DK200900369A (fi)
FI (1) FI124122B (fi)
GB (1) GB2454620B (fi)
HK (1) HK1127282A1 (fi)
IL (1) IL197518A0 (fi)
IS (1) IS8808A (fi)
MY (1) MY157716A (fi)
NZ (1) NZ575422A (fi)
PT (1) PT2008032107W (fi)
RU (1) RU2423975C2 (fi)
SE (1) SE0900332L (fi)
SK (1) SK288460B6 (fi)
TR (1) TR200901984T1 (fi)
TW (1) TWI399223B (fi)
WO (1) WO2008032107A1 (fi)
ZA (1) ZA200810616B (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113420A1 (ja) * 2008-03-13 2009-09-17 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
TW201000097A (en) * 2008-05-30 2010-01-01 Daiichi Sankyo Co Ltd Medicament for the prophylaxis or treament of hypertension
US20120115837A1 (en) * 2009-04-30 2012-05-10 Takeda Pharmaceutical Company Limited Solid Preparation
PL2538924T3 (pl) * 2010-02-24 2014-10-31 Sanofi Aventis Deutschland Stałe formulacje farmaceutyczne ramiprylu i benzenosulfonianu amlodypiny oraz ich wytwarzanie
EP2425859A1 (en) * 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
CN102028663B (zh) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
CN103565807B (zh) * 2012-07-25 2015-11-04 天津市汉康医药生物技术有限公司 一种奥美沙坦酯氨氯地平药物组合物
KR101778050B1 (ko) * 2012-10-12 2017-09-13 이에이 파마 가부시키가이샤 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
JPWO2014188729A1 (ja) * 2013-05-24 2017-02-23 持田製薬株式会社 経口用組成物
EP2883539A1 (en) 2013-12-12 2015-06-17 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of olmesartan and amlodipine
CN104739799B (zh) * 2013-12-27 2018-01-05 辰欣药业股份有限公司 一种用于直接压片的苯磺酸氨氯地平组合物及其片剂制备方法
KR102222917B1 (ko) * 2014-06-25 2021-03-05 한림제약(주) 암로디핀 및 올메사탄 메독소밀을 포함하는 약학 조성물
CN104997778A (zh) * 2015-07-08 2015-10-28 南京正大天晴制药有限公司 一种奥美沙坦酯氨氯地平药物组合物
CN105902510A (zh) * 2015-12-24 2016-08-31 嘉实（湖南）医药科技有限公司 一种奥美沙坦酯氨氯地平复方制剂的制备工艺
MX2021010183A (es) * 2019-02-26 2021-09-21 Daewoong Pharmaceutical Co Ltd Composicion farmaceutica con forma de dosificacion unica para tratar o prevenir la hipertension y la hiperlipidemia.
CN115300476B (zh) * 2022-09-01 2024-04-16 华润双鹤药业股份有限公司 一种药物组合物及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) 1962-03-13 Reduction of i
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4772596A (en) * 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
US5260285A (en) * 1990-12-07 1993-11-09 Merck & Co., Inc. Substituted imidazopyridazines as angiotensin II antagonists
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH05967A (ja) * 1991-06-19 1993-01-08 Yamanouchi Pharmaceut Co Ltd 組織プラスミノーゲンアクチベーター含有製剤組成物
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US5808084A (en) * 1996-02-14 1998-09-15 Pfizer, Inc. Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
KR100540618B1 (ko) * 1996-07-15 2006-01-12 상꾜 가부시키가이샤 의약 조성물
WO1999000383A1 (en) * 1997-06-27 1999-01-07 Smithkline Beecham Corporation Eprosartan monohydrate
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US20030022928A1 (en) * 1998-03-11 2003-01-30 Smithkline Beecham Corporation Novel compositions of eprosartan
US20020127254A1 (en) * 1998-06-25 2002-09-12 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
DK1466889T3 (da) * 1999-04-06 2008-09-08 Sepracor Inc O-Desmethylvenlafaxin-succinat
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
EP1867342A1 (en) * 1999-07-21 2007-12-19 Takeda Pharmaceutical Company Limited Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
CN100450483C (zh) * 2000-04-11 2009-01-14 三共株式会社 含有钙阻滞剂的稳定药物组合物
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
CA2464561A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
HUP0301537A3 (en) * 2003-06-03 2005-07-28 Egis Gyogyszergyar Nyilvanosan Deramcyclane fumarate tablets and process for producing them
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
EP1784398A1 (en) * 2004-09-02 2007-05-16 Teva Pharmaceutical Industries Ltd Purification of olmesartan medoxomil
JP2006176496A (ja) * 2004-11-24 2006-07-06 Freunt Ind Co Ltd 固形剤およびその製造方法
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US7563814B2 (en) * 2005-01-03 2009-07-21 Teva Pharmaceutical Industries Ltd. Olmesartan medoxomil with reduced levels of impurities
CA2604190A1 (en) * 2005-04-20 2006-11-02 Merck & Co., Inc. Angiotensin ii receptor antagonists
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
JP5148296B2 (ja) * 2005-06-27 2013-02-20 第一三共株式会社 アンジオテンシンｉｉ受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
EP1928409B1 (en) * 2005-09-12 2012-09-12 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CN101360725B (zh) * 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
JP2007145646A (ja) * 2005-11-28 2007-06-14 Asahi Glass Co Ltd プレス成型装置及びプレス成型装置の搬送品搬送方法
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.

Also Published As

Publication number Publication date
SE0900332L (sv) 2009-06-12
GB2454620A (en) 2009-05-13
NZ575422A (en) 2011-01-28
AU2007297333B2 (en) 2010-10-28
MY157716A (en) 2016-07-15
ZA200810616B (en) 2009-08-26
FI20090094A (fi) 2009-03-13
TWI399223B (zh) 2013-06-21
SK50212009A3 (sk) 2009-06-05
WO2008032107A1 (en) 2008-03-20
DE212007000063U1 (de) 2009-05-14
AT509493A5 (de) 2011-09-15
AU2007297333A1 (en) 2008-03-20
IS8808A (is) 2009-03-12
CH703897B1 (de) 2012-04-13
RU2009114166A (ru) 2010-10-20
US20090175942A1 (en) 2009-07-09
FI124122B (fi) 2014-03-31
BRPI0716893A2 (pt) 2014-05-06
US20160129008A1 (en) 2016-05-12
GB2454620B (en) 2011-08-17
SK288460B6 (sk) 2017-03-01
AT509493B1 (de) 2012-01-15
IL197518A0 (en) 2009-12-24
RU2423975C2 (ru) 2011-07-20
PT2008032107W (pt) 2013-07-09
JP5344620B2 (ja) 2013-11-20
DK200900369A (en) 2009-03-16
TR200901984T1 (tr) 2009-08-21
JP2011500505A (ja) 2011-01-06
GB0903844D0 (en) 2009-04-22
TW200817052A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
GB2454620B (en) Solid dosage form of olmesartan medoxomil and amlodipine
IL181549A0 (en) Preparation of olmesartan medoxomil
IL195797A0 (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
ZA200810116B (en) Pharmaceutical composition comprising amlodipine and losartan
HK1163539A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EP2083864A4 (en) ANTAGONISTS OF PCSK9
EP2083859A4 (en) ANTAGONISTS OF PCSK9
EP2083860A4 (en) PCSK9 ANTAGONISTS
EP2106261A4 (en) ANTAGONISTS OF PCSK9
HK1117519A1 (en) Substituted benzimidazoles and methods of preparation
ZA200804803B (en) Dosage element and chamber
EP2074142A4 (en) COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
IL181550A0 (en) Purification of olmesartan medoxomil
IL212880A0 (en) Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
ZA201005442B (en) Pharmaceutical compositions of amlodipine and valsartan
EP2070919A4 (en) SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
ZA200808073B (en) Methods and compositions for antagonism of rage
GB0616794D0 (en) Solid dosage form
EP2114404A4 (en) COMPOUND AND PHARMACEUTICAL COMPOSITION
GB201018110D0 (en) Solid dosage form of olmesartan medoxomil, amiodipine and hydrochlorothiazide
PL388087A1 (pl) Forma stała medoksomilu olmesartanu i amlodypiny
GB0621582D0 (en) Dosage element and chamber
ZA200800536B (en) Substituted benzimidazoles and methods of preparation

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE FILING DATE OF THE PRIORITY APPLICATION FROM 15.09.2008 TO 15.09.2006